A5026064663- Hearing, Cochlea, Tinnitus, Genetics
- Ear and Head Tumors
- Childhood Cancer Survivors' Quality of Life
- Hearing Loss and Rehabilitation
- Vestibular and auditory disorders
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Cancer therapeutics and mechanisms
- Full-Duplex Wireless Communications
- Fungal Infections and Studies
- Head and Neck Surgical Oncology
- Cystic Fibrosis Research Advances
- Family Support in Illness
- Renal and related cancers
- Antifungal resistance and susceptibility
- Ear Surgery and Otitis Media
- Synthesis of Organic Compounds
- DNA Repair Mechanisms
- Cancer-related molecular mechanisms research
- Reproductive Biology and Fertility
- Polyomavirus and related diseases
- Pediatric health and respiratory diseases
- Family and Disability Support Research
- Sarcoma Diagnosis and Treatment
Princess Máxima Center
2018-2024
Wilhelmina Children's Hospital
2024
Cisplatin is an essential chemotherapeutic agent for children treated with hepatic tumors, neuroblastoma, medulloblastoma, germ cell and osteosarcoma. Unfortunately, cisplatin-induced hearing loss (CIHL) occurs in about 50% of children,1-3 more frequent severe those aged less than or equal to 5 years.4, CIHL develops during the early stages therapy,4 irreversible,6 infants young causes speech language deficits, impaired academic skills, lower quality life.7, 8 Prevention has been variously...
Background Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development cisplatin‐induced hearing loss (CIHL) over time in children with cancer by age and examined influence other clinical characteristics on course CIHL. Methods Data from Canadian patients childhood were retrospectively reviewed. Hearing was graded according to International Society Pediatric Oncology criteria. Kaplan‐Meier method applied estimate cumulative incidence CIHL for total...
Ototoxicity is a devastating direct, irreversible side effect of platinum use in children with cancer, its consequent on speech, language and social development, quality life adult productivity. Cisplatin, an essential chemotherapeutic agent for the treatment solid tumors children, DNA cross-linking agent. Which causes hearing loss 50-70% cisplatin treated children. Fortunately, to prevent loss, sodium thiosulfate (STS), which binds cisplatin, reduces superoxides both tumor outer hair cells...
Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part the supportive care pathway enables early detection hearing loss, decision-making about ongoing treatment, and, when applicable, timely use audiologic interventions. Pediatric oncologic clinical practice treatment trials have tended to be driven by tumor type tumor-specific working groups. Internationally accepted standardized recommendations for...
ABSTRACT Introduction Ototoxicity is an adverse effect of childhood cancer treatment with a negative impact on speech‐language development and quality life. This study aimed to retrospectively assess ototoxicity monitoring in national cohort pediatric patients solid tumors, examining the frequency determinants associated hearing loss (HL). Methods retrospective included 305 treated between 2015 2020 at Princess Máxima Center. Patients receiving platinum agents, head neck radiotherapy, and/or...
Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common effect children treated cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity extend from high-tone hearing involvement speech frequencies. impede language neurocognitive development. Although treatment-related risk factors...
Abstract In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using genome-wide association study (GWAS) approach, we identified variant TCERG1L (rs893507) to be associated hearing loss 390 non-cranial irradiated, cisplatin-treated cancer. These results were replicated two independent, similarly treated cohorts ( n = 192 and 188, respectively) (combined cohort: P 5.3 × 10 −10 , OR 3.11, 95% CI 2.2–4.5)....
Tinnitus is a serious late effect of childhood cancer treatment. The aim this study was to determine the occurrence and risk factors for tinnitus in national cohort survivors (CCS).Data were collected within Dutch Childhood Oncology Group - Long-Term Effects after Cancer (DCOG-LATER) by self-reported health questionnaire among 5327 CCS treated between 1963 2002. Siblings (N = 1663) invited complete same questionnaire. Relevant patient characteristics treatment obtained from LATER database....
Cisplatin, widely used in the treatment of solid tumors, causes permanent hearing loss more than 60% treated children. Previous studies have implicated several clinical factors development ototoxicity, including cumulative cisplatin dose. However, role dose intensity children remains unclear. Pharmacogenetic also identified genetic variants TPMT that increase risk cisplatin-induced loss. This study aims to determine whether contributes and variations further modifies loss.The authors...
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in children with cancer. Studies on the clinical characteristics IFI solid tumors limited. This Dutch retrospective cohort study reviewed medical records 61 to analyze during their full treatment period. Seven episodes were reported 6/61 patients (10%), all diagnosed intermediate-risk or high-risk Wilms tumor neuroblastoma. Larger studies necessary reveal determinants this group value prophylaxis.
Purpose: The frequency and patterns of HL in a HNRMS survivor cohort were investigated. A dose–effect relationship between the dose to cochlea was explored. Methods: Dutch survivors treated for 1993 2017 with no relapse at least two years after end treatment eligible inclusion. evaluated pure-tone audiometry. graded according Muenster, Common Terminology Criteria Adverse Events (CTCAE) v4.03 International Society Paediatric Oncology (SIOP) classification. We defined deleterious as Muenster ≥...
<sec> <title>BACKGROUND</title> Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common effect children treated cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity extend from high-tone hearing involvement speech frequencies. impede language neurocognitive development. Although...
Some children with central nervous system (CNS) and solid tumors are at risk to develop ototoxicity during treatment. Up now, several factors have been identified that may contribute ototoxicity, such as platinum derivates, cranial irradiation, brain surgery. Comedication, like antibiotics diuretics, is known enhance but their independent influence has not investigated in childhood cancer patients. Recommendations for hearing loss screening missing or vary highly across treatment protocols....
<sec> <title>BACKGROUND</title> Some children with central nervous system (CNS) and solid tumors are at risk to develop ototoxicity during treatment. Up now, several factors have been identified that may contribute ototoxicity, such as platinum derivates, cranial irradiation, brain surgery. Comedication, like antibiotics diuretics, is known enhance but their independent influence has not investigated in childhood cancer patients. Recommendations for hearing loss screening missing or vary...